Valiant Laboratories Ltd – The Paracetamol Player With 9,000 Problems (and Counting)
1. At a Glance
Valiant Laboratories Ltd (VLL) is basically India’s dedicated paracetamol factory. Incorporated in 1980, listed in 2023, and somehow already earning CRISIL downgrades by 2024—this company’s journey is like a Bollywood remake of Gabbar Singh: too much drama, too little substance. With a 9,000 MTPA Palghar plant, they churn out paracetamol in every possible form—powder, crystal, fine powder, maybe even dust if margins slip further. Market cap? ₹474 crore. Net profit? ₹0.13 crore. In other words—India consumes crores of Crocins daily, yet this company still looks like it took the wrong medicine.
2. Introduction
If you thought selling paracetamol was a “stable business”, think again. This company has managed to turn a pain-reliever into a pain-generator for its shareholders.
Let’s set the scene:
IPO in 2023 raised ₹152 crore. Retail rushed in because “paracetamol toh roz chahiye yaar”.
Within two years, sales shrank from ₹334 crore (FY23) to ₹133 crore (FY25). That’s not a slowdown—it’s like falling off a treadmill while trying to run.
CRISIL downgraded them twice in 2024. That’s like your tuition teacher telling your parents: “Beta bilkul hi hopeless hai.”
Net margins? Let’s just say 0% is aspirational.
And yet, the promoters sit pretty with 74.9% holding, watching public shareholders nurse headaches worse than the ones this company supposedly treats.
Question for you: if India is the world’s largest paracetamol consumer, why is Valiant acting like it’s selling snow boots in Chennai?
3. Business Model – WTF Do They Even Do?
At its core, VLL is an API maker. Their focus is paracetamol—the universal painkiller, fever fixer, and “doctor ka default option.”
Products: API in powder, fine powder, and crystal form. Fancy way of saying “grind it differently, sell it at same price.”
End Uses: Tablets, capsules, syrups. In short: every time you pop a Dolo-650, someone else (not them) is making the real money.
Capacity: Palghar plant with 9,000 MTPA, GMP and ISO certified. Great on paper, but utilization looks like an Indian gym membership—hardly used.
Subsidiary Adventure: Invested ₹165 crore in Valiant Advanced Sciences Pvt Ltd. Gave loans of ₹198 crore and got them back. Basically, they’re rotating cash faster than you rotate parathas on a tawa.
Business model summary: buy raw material, process into API, sell at wafer-thin margins. Repeat until either debt rises or CRISIL scolds you again.
4. Financials Overview
Quarterly Numbers (₹ Cr):
Source table
Metric
Jun’25 (Latest)
Jun’24 (YoY)
Mar’25 (QoQ)
YoY %
QoQ %
Revenue
46.8
18.9
57.8
148%
-19%
EBITDA
2.4
-2.4
3.8
NA
-37%
PAT
1.8
-0.5
0.7
457%
160%
EPS (₹)
0.34
-0.09
0.13
NA
162%
Commentary:
YoY, they look like a turnaround story (148% sales growth, PAT from -ve to +ve).
QoQ, they’re already falling back to bad habits (-19% revenue).
EPS at ₹0.34 means annualized ~₹1.36. At CMP of ₹87, that’s a P/E of ~64 (ignoring the “3642” Screener glitch). Pharma peers trade at 20–30 P/E. Translation? Even paracetamol won’t cure this valuation fever.
5. Valuation – Fair Value Range Only
Method 1: P/E Multiple
Annualized EPS: ₹1.36
Reasonable Pharma P/E: 20–30x
Fair Value = ₹27–41
Method 2: EV/EBITDA
Annualized EBITDA (Q1FY26 x4): ~₹10 cr
EV/EBITDA for small pharma: 10–12x
Enterprise Value = ₹100–120 cr
Less Debt = ₹122 cr, Add Cash ~₹7 cr → Equity Value basically zero to slightly negative.
Method 3: DCF (simplified)
Assume 8% sales growth, 5% margins (if they ever reach).
5-year DCF suggests ₹35–45 per share.
Fair Value Range (Educational Only): ₹27 – ₹45 (Disclaimer: This range is for educational purposes only and not investment advice.)
6. What’s Cooking – News, Triggers, Drama
IPO (Oct 2023): Raised ₹152 crore. Great entry, terrible afterparty. Stock down 30% since.
Subsidiary Saga: Pumped ₹165 crore into VASPL. Nobody knows what magic will happen there.
Rights Issue (Jul 2025): Board approved ₹81.5 crore fundraise. When business fails, equity holders are the new
